CytoDyn Revenue and Competitors
Estimated Revenue & Valuation
- CytoDyn's estimated annual revenue is currently $1.9M per year.
- CytoDyn's estimated revenue per employee is $77,500
- CytoDyn's total funding is $89.5M.
Employee Data
- CytoDyn has 24 Employees.
- CytoDyn grew their employee count by 4% last year.
CytoDyn's People
| Name | Title | Email/Phone |
|---|---|---|
1 | EVP, Legal Affairs | Reveal Email/Phone |
2 | SVP, Business Operations | Reveal Email/Phone |
3 | VP Operations | Reveal Email/Phone |
4 | Head Research & Basic Science | Reveal Email/Phone |
5 | Chief Medical Officer | Reveal Email/Phone |
6 | Director | Reveal Email/Phone |
7 | Chief Financial Officer | Reveal Email/Phone |
8 | Director, President and CEO | Reveal Email/Phone |
9 | Senior Director Clinical Operations | Reveal Email/Phone |
10 | Senior Director, Head Biostatistics | Reveal Email/Phone |
CytoDyn Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $3.1M | 40 | 18% | $40M | N/A |
#2 | $0.2M | 2 | 0% | N/A | N/A |
#3 | $1.3M | 17 | -15% | N/A | N/A |
#4 | $2.6M | 17 | 6% | N/A | N/A |
#5 | $12.9M | 83 | 5% | N/A | N/A |
#6 | $1.9M | 24 | 4% | $89.5M | N/A |
#7 | $2.8M | 18 | 6% | N/A | N/A |
#8 | $40.3M | 260 | 21% | N/A | N/A |
#9 | $0.9M | 6 | 0% | N/A | N/A |
#10 | $0.6M | 4 | -20% | N/A | N/A |
What Is CytoDyn?
CytoDyn, Inc. is a Colorado corporation with its home office in Glorieta, NM. The Company\'s shares are quoted on the Pink Sheets under the symbol CYDY. Previously we periodically reported our financial condition and results of operations in our SEC Filings. \"Cytolin\" and \"CytoDyn\" (as used to identify a particular class of products) are the registered trademarks of CytoDyn, Inc. Our graphic logo is the registered mark of CytoDyn, Inc. Member New Mexico Biotechnology and Biomedical Association
keywords:Biotechnology
$89.5M
Total Funding
24
Number of Employees
$1.9M
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CytoDyn News
CytoDyn Inc (OTCMKTS: CYDY) is moving northbound after another test of $0.23 lows. The stock was one of the biggest runners of 2020...
(OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for...
With CytoDyn's lead drug on FDA clinical hold, the troubled biotech will go searching for partners to rescue key programs and keep afloat.
(CytoDyn Photo via investor webcast) Investors in a biotech startup developing a COVID-19 treatment claim the firm’s leaders cashed out as stock prices surged during a publicity blitz for a drug that has yet to show any value as coronavirus medicine. CytoDyn, a 19-year-old company headquartere ...
Company Achieves Total Financing in April of $57 Million VANCOUVER, Washington, April 22, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140), a CCR5 antagonist with the potential for ...
Other Companies in Vancouver
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.2M | 24 | -8% | N/A |
#2 | $2.5M | 24 | -8% | N/A |
#3 | $2.4M | 24 | N/A | N/A |
#4 | $2.4M | 24 | N/A | N/A |
#5 | $3.5M | 24 | N/A | N/A |